Evidence map›Paper›PMID 20570882›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2010

Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis.

Imad Shureiqi, Dongning Chen, R Sue Day, Xiangsheng Zuo, Fredric Lyone Hochman, William A Ross, Rhonda A Cole, Ofie Moy, Jeffrey S Morris, Lianchun Xiao and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.Cancer prevention research (Philadelphia, Pa.) · 2011
    Trial
  6. Review
  7. Lipoxygenases at the Intersection of Infection and Carcinogenesis.International journal of molecular sciences · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Influence of Lipoxygenase Inhibition on Glioblastoma Cell Biology.International journal of molecular sciences · 2020
    Article
  16. Article
  17. Review
  18. Review
  19. ALOX15 as a suppressor of inflammation and cancer: Lost in the link.Prostaglandins & other lipid mediators · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Imad ShureiqiDepartment of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, 77030-4009, USA. ishureiqi@mdandesron.org
Dongning Chen
R Sue Day
Xiangsheng Zuo
Fredric Lyone Hochman
William A Ross
Rhonda A Cole
Ofie Moy
Jeffrey S Morris
Lianchun Xiao
Robert A Newman
Peiying Yang
Scott M Lippman
Michael E. DeBakey VA Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

5-LOX-1 and Clinical Chemoprevention of Colon TumorsR01CA106577 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHUREIQI, IMAD · 2005 to 2008
$1.3M
15-LOX-1 effects on colitis and colon cancerR01CA137213 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHUREIQI, IMAD · 2009 to 2012
$1.3M
LINOLEIC ACID METABOLISM AND COLON CARCINOGENESISK07CA086970 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI SHUREIQI, IMAD · 2000 to 2005
$680k
NCI NIH HHS CA137213NCI NIH HHS K07 CA086970NCI NIH HHS K07 CA86970NCI NIH HHS R01 CA106577NCI NIH HHS R01 CA137213
6 · The paper itself

Abstract

Lipoxygenases (LOX) are key enzymes for the oxidative metabolism of polyunsaturated fatty acids into biologically active products. Clinical data on comparative levels of various LOX products in tumorigenesis are lacking. Therefore, we examined the profiles of several LOX products (5-LOX, 12-LOX, 15-LOX-1, and 15-LOX-2) by liquid chromatography/tandem mass spectrometry in the major steps of colorectal tumorigenesis (normal, polyp, and cancer) in a clinical study of 125 subjects (49 with normal colon, 36 with colorectal polyps, and 40 with colorectal cancer) who underwent prospective colorectal biopsies to control for various potential confounding factors (e.g., diet, medications). Mean 13-hydroxyoctadecadienoic acid (13-HODE) levels were significantly higher in normal colon [mean, 36.11 ng/mg protein; 95% confidence interval (95% CI), 31.56-40.67] than in paired colorectal cancer mucosa (mean, 27.01 ng/mg protein; 95% CI, 22.00-32.02; P = 0.0002), and in normal colon (mean, 37.15 ng/mg protein; 95% CI, 31.95-42.34) than in paired colorectal polyp mucosa (mean, 28.07 ng/mg protein; 95% CI, 23.66-32.48; P < 0.001). Mean 13-HODE levels, however, were similar between the left (mean, 37.15 ng/mg protein; 95% CI, 31.95-42.35) and the right normal colon (mean, 32.46 ng/mg protein; 95% CI, 27.95-36.98; P = 0.09). No significant differences with regard to 12- or 15-hydroxyeicosatetraenoic acid or leukotriene B(4) levels were detected between normal, polyp, and cancer mucosae. 15-LOX-1 inhibited interleukin-1beta expression. This study establishes that reduced 13-HODE levels are a specific alteration in the LOX product profile associated with human colorectal tumorigenesis.

Indexed as

AgedAged, 80 and overBiopsyColorectal NeoplasmsFemaleGastric MucosaHumansInterleukin-1betaLinoleic AcidsLipoxygenaseMaleMiddle Aged13-hydroxy-9,11-octadecadienoic acidInterleukin-1betaLinoleic AcidsLipoxygenase

Identifiers

PMID20570882
PMCPMC2900425
OpenAlexW2170661234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.